Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.
Ranbaxy is India’s leading pharmaceutical company, one of only a handful so far to achieve international prominence. Manufacturing is conducted mainly in India, but also in other countries.
In June 2008, in a surprise move, Daiichi Sankyo announced plans to acquire Ranbaxy in a deal which valued Ranbaxy at US$8.5 billion. The acquisition was completed in October 2008. As a result, the two firms are undergoing a reorganisation process to combine their strengths.
In 2004, revenues broke the US$1 billion mark for the first time. In 2009, Ranbaxy recorded total consolidated revenues worth Rs80,837.0 million (US$1,670.9 million). Profit after tax reached Rs2,964.9 million (US$61.3 million), compared to a loss of Rs9,512.1 million in 2008.
The company claims its long term aim is to move away from generics and into original drug research. This is partly spurred by the tightening of India’s patent laws which began in 2005. The firm is undertaking research into a new anti-malarial product.
Table Of Contents
Ranbaxy Generics Company Intelligence Report Table of Contents
Executive Summary 1 Introduction 2 Acquisition by Daiichi Sankyo 2 FDA action 2 Products 3 New Drug Discovery research 4 Pharmaceutical Research (dosage forms) 5 Chemical Research (active pharmaceutical ingredients) 5 Ranbaxy Laboratories: international regulatory filings and approvals, 2009 5 Ranbaxy ANDA Approvals, January 2002 -September 2010 6 Ohm Laboratories ANDA Approvals, January 2002 - September 2010 8 Antiretrovirals 8 Recent product approvals 9 Prasugrel (India) 9 Atorvastatin (South Africa) 9 Valacyclovir (US) 9 Atorvastatin (Canada) 10 Ranbaxy to launch olmesartan medoxomil in six African countries 10 Raloxifien (Romania) 10 Calcitriol (authorised generic, US) 11 Glycopyrrolate (US) 11 Sumatriptan (US) 11 Losartan (Malaysia) 11 Ropinirole (Canada) 11 Simvastatin (Canada) 11 Amlodipine (Canada) 12 Financial results 13 Latest Quarter Results - Q310 13 Ranbaxy Laboratories: consolidated quarterly results, in Rs millions 13 Ranbaxy Laboratories: consolidated quarterly results, in US$ millions 13 Latest Fiscal Year Results - FY2009 14 Ranbaxy Laboratories: consolidated fiscal year results, in Rs millions 14 Ranbaxy Laboratories: consolidated fiscal year results, in US$ millions 14 Ranbaxy Laboratories: consolidated fiscal year sales by region, in Rs millions 15 Ranbaxy Laboratories: consolidated fiscal year sales by region, in US$ millions 15 Major developments 15 Ranbaxy sets up South African manufacturing facility 15 Daiichi Sankyo to use Ranbaxy to market levofloxacin product in Romania, South Africa 16 Ranbaxy's New Drug Discovery Research arm transferred to Daiichi Sankyo 16 Daiichi Sankyo to launch innovator products in Mexico through Ranbaxy subsidiary 16 Ohm Laboratories receives FDA Warning Letter 17 Ranbaxy and Nippon Chemiphar dissolve Japanese joint venture 17 Ranbaxy relocates European headquarters 17 South African Competition Commission places conditions on Aspen / GlaxoSmithKline agreement 18 Ranbaxy gains Japanese GMP approval for non-sterile plant 18 Daiichi acquires Ranbaxy 19 Mergers, acquisitions and agreements 20 Ranbaxy and Pfenex announce biosimilar development agreement 20 Syntropharma signs agreement with Ranbaxy 21 Ranbaxy acquires product rights and facility from Biovel 21 Ranbaxy transfers shareholding in Ranbaxy (Guangzhou China) 21 Litigation 22 Companies settle pioglitazone challenges 22